Tumor-derived circulating endothelial cells as a biomarker in locally advanced and metastatic clear cell renal cell carcinoma
- Conditions
- clear cell renal cell carcinomakidney cancer10038364
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 75
Inclusion Criteria
* Patients with locally advanced or metastatic ccRCC
* Candidate for receiving first-line therapy with sunitinib or pazopanib
* Age * 18 years
* Written informed consent
Exclusion Criteria
* Serious illness or medical unstable condition prohibiting adequate treatment and follow-up
* Previous treatment with systemic therapy for ccRCC
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary endpoint is to explore if the presence of CD276-positive CECs in<br /><br>locally advanced or metastatic ccRCC patients before the start of VEGFR-TKI<br /><br>based therapy, is worth more investigation. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary endpoints are to explore whether a CEC count * 8 CD276-positive CECs<br /><br>for start of the therapy is associated with the PFS at 12 months. Furthermore,<br /><br>we will explore if changes in the CD276-positive CEC count measured 4 weeks<br /><br>after start of first-line VEGFR-TKI based therapy are associated with the PFS<br /><br>at 12 months.</p><br>